Altum Pharmaceuticals Inc. has closed a new round of financing, raising $#Research Note – Subscribers ONLY – where and how did you get your news? Subscribe today to see our research on this and all other subscriber ONLY news. Be informed!#
Vancouver based Altum Pharmaceuticals Inc. is a private biopharmaceutical company engaged in clinical and commercial development of novel natural and pharmaceutical compounds, to treat cancer and autoimmune disorders. Altum focuses on development and acquisition of novel products specializing on the commercialization of existing products for cancer and diseases mediated by acute and chronic inflammatory reactions.
photo credit: Altum Pharmaceuticals
Ted Liu
Ted Liu, M.Sc. (Mining, Queen's), MBA (Finance, Toronto), is the Editor of Private Capital Journal, CanadaMetals.ca, TechWire.ca, and the former Editor of Canadian Private Equity. Ted has been passionately tracking Canadian private capital industry since 1992, having most recently served as Research Director for The Canadian Venture Capital and Private Equity Association (CVCA).
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- Audax Private Equity’s Lifemark Health Group acquires AssessMed - December 5, 2019
- Persistence Capital Partners launches MedSpa Partners - December 5, 2019
- Thoughtexchange secures $20M Series B led by IVP - December 5, 2019
